Cargando…
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis
Malignant gliomas are difficult to treat in clinical practice. This study was aimed to investigate the preclinical efficacy of CRLX101, an investigational nanoparticle-drug conjugate developed by conjugating camptothecin (CPT) with cyclodextrin-polyethylene glycol, against gliomas. CPT fluorescence...
Autores principales: | Lin, Chien-Ju, Lin, Yi-Ling, Luh, Frank, Yen, Yun, Chen, Ruei-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173144/ https://www.ncbi.nlm.nih.gov/pubmed/27285755 http://dx.doi.org/10.18632/oncotarget.9878 |
Ejemplares similares
-
CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
por: Young, Cissy, et al.
Publicado: (2011) -
Development of a Prodrug of Camptothecin for Enhanced
Treatment of Glioblastoma Multiforme
por: Checa-Chavarria, Elisa, et al.
Publicado: (2021) -
A Systematic Review of Clinical Trials on the Efficacy and Safety of CRLX101 Cyclodextrin-Based Nanomedicine for Cancer Treatment
por: Serrano-Martínez, Ana, et al.
Publicado: (2023) -
Antiangiogenesis in recurrent glioblastoma: proof of principle
por: Nossek, Erez, et al.
Publicado: (2009) -
Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells
por: CHANG, KEN-HU, et al.
Publicado: (2013)